Krystle N. Agans

Krystle N. Agans

Auto-generated profile, based on publicly available information

Krystle N. Agans

Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2017 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Chad MireChad Mire
Chad Mire
RCRobert W Cross
Robert W Cross
JGJoan B Geisbert
Joan B Geisbert
VBViktoriya Borisevich
Viktoriya Borisevich
KAKrystle N Agans
Krystle N Agans
Thomas W GeisbertThomas W Geisbert
Thomas W Geisbert

25 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
RCRobert W. Cross
Robert W. Cross
ZBZachary A. Bornholdt
Zachary A. Bornholdt
APAbhishek Prasad
Abhishek Prasad
VBViktoriya Borisevich
Viktoriya Borisevich
KAKrystle N. Agans
Krystle N. Agans
Thomas W GeisbertThomas W Geisbert
Thomas W Geisbert
Monoclonal antibodies (mAbs) and remdesivir, a small-molecule antiviral, are promising monotherapies for many viruses, including members of the genera Marburgvirus and Ebolavirus (family Filoviridae), and more recently, SARS-CoV-2. One of the major challenges of acute viral infections is the treatment of advanced disease. Thus, extending the window of therapeutic intervention is critical. Here, we explore the benefit of combination therapy with a mAb and remdesivir in a non-human primate model of Marburg virus (MARV) disease. While rhesus monkeys are protected against lethal infection when treatment with either a human mAb (MR186-YTE; 100%), or remdesivir (80%), is initiated 5 days post-inoculation (dpi) with MARV, no animals survive when either treatment is initiated alone beginning 6 dpi. However, by combining MR186-YTE with remdesivir beginning 6 dpi, significant protection (80%) is achieved, thereby extending the therapeutic window. These results suggest value in exploring combination therapy in patients presenting with advanced filovirus disease.

13 December 2013 in Virology Journal
Verified
Journal Article
Open access
PDF file
Chad MireChad Mire
Chad Mire
KVKrista M Versteeg
Krista M Versteeg
RCRobert W Cross
Robert W Cross
KAKrystle N Agans
Krystle N Agans
KFKarla A. Fenton
Karla A. Fenton
Thomas W GeisbertThomas W Geisbert
Thomas W Geisbert
Nipah virus (NiV) is a highly pathogenic zoonotic agent in the family Paramyxoviridae that is maintained in nature by bats. Outbreaks have occurred in Malaysia, Singapore, India, and Bangladesh and have been associated with 40 to 75% case fatality rates. There are currently no vaccines or postexposure treatments licensed for combating human NiV infection.

9 December 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RCRobert W. Cross
Robert W. Cross
RXRong Xu
Rong Xu
DMDemetrius Matassov
Demetrius Matassov
SHStefan Hamm
Stefan Hamm
TLTheresa E. Latham
Theresa E. Latham
Thomas W GeisbertThomas W Geisbert
Thomas W Geisbert
Recent occurrences of filoviruses and the arenavirus Lassa virus (LASV) in overlapping endemic areas of Africa highlight the need for a prophylactic vaccine that would confer protection against all of these viruses that cause lethal hemorrhagic fever (HF). We developed a quadrivalent formulation of VesiculoVax that contains recombinant vesicular stomatitis virus (rVSV) vectors expressing filovirus glycoproteins and that also contains a rVSV vector expressing the glycoprotein of a lineage IV strain of LASV. Cynomolgus macaques were vaccinated twice with the quadrivalent formulation, followed by challenge 28 days after the boost vaccination with each of the 3 corresponding filoviruses (Ebola, Sudan, Marburg) or a heterologous contemporary lineage II strain of LASV. Serum IgG and neutralizing antibody responses specific for all 4 glycoproteins were detected in all vaccinated animals. A modest and balanced cell-mediated immune response specific for the glycoproteins was also detected in most of the vaccinated macaques. Regardless of the level of total glycoprotein-specific immune response detected after vaccination, all immunized animals were protected from disease and death following lethal challenges. These findings indicate that vaccination with attenuated rVSV vectors each expressing a single HF virus glycoprotein may provide protection against those filoviruses and LASV most commonly responsible for outbreaks of severe HF in Africa.

14 March 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SFStephanie L. Foster
Stephanie L. Foster
CWCourtney Woolsey
Courtney Woolsey
VBViktoriya Borisevich
Viktoriya Borisevich
KAKrystle N. Agans
Krystle N. Agans
APAbhishek Prasad
Abhishek Prasad
Thomas W GeisbertThomas W Geisbert
Thomas W Geisbert
Significance: Concern has increased about the pandemic potential of Nipah virus (NiV). Similar to SARS-CoV-2, NiV is an RNA virus that is transmitted by respiratory droplets. There are currently no NiV vaccines licensed for human use. While several preventive vaccines have shown promise in protecting animals against lethal NiV disease, most studies have assessed protection 1 mo after vaccination. However, in order to contain and control outbreaks, vaccines that can rapidly confer protection in days rather than months are needed. Here, we show that a recombinant vesicular stomatitis virus vector expressing the NiV glycoprotein can completely protect monkeys vaccinated 7 d prior to NiV exposure and 67% of animals vaccinated 3 d before NiV challenge.

17 March 2022 in Cell
Verified
Journal Article
Open access
JMJacob C. Milligan
Jacob C. Milligan
CDCarl W. Davis
Carl W. Davis
XYXiaoying Yu
Xiaoying Yu
PIPhilipp A. Ilinykh
Philipp A. Ilinykh
Kai HuangKai Huang
Kai Huang
ESErica Ollmann Saphire
Erica Ollmann Saphire
Several ebolaviruses cause outbreaks of severe disease. Vaccines and monoclonal antibody cocktails are available to treat Ebola virus infections, but not Sudan virus or other ebolaviruses. Current cocktails contain antibodies that cross-react with the secreted soluble glycoprotein (sGP) that absorbs virus-neutralizing antibodies. By sorting memory B cells from EBOV infection survivors, we isolated two broadly reactive anti-GP monoclonal antibodies, 1C3 and 1C11, that potently neutralize, protect rodents from disease, and lack sGP cross-reactivity. Both antibodies recognize quaternary epitopes in trimeric ebolavirus GP. 1C11 bridges adjacent promoters via the fusion loop. 1C3 has a tripartite epitope in the center of the trimer apex. One 1C3 antigen-binding fragment anchors simultaneously to the three receptor-binding sites in the GP trimer, and separate 1C3 paratope regions interact differently with identical residues on the three protomers. A cocktail of both antibodies completely protected nonhuman primates from EBOV and SUDV disease, indicating their potential clinical value.